Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Interest Expenses (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Interest Expenses for 16 consecutive years, with $6835.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest Expenses changed 0.12% year-over-year to $6835.0, compared with a TTM value of -$76663.0 through Sep 2025, down 353.05%, and an annual FY2024 reading of $27353.0, down 10.53% over the prior year.
  • Interest Expenses was $6835.0 for Q3 2025 at China Pharma Holdings, up from $6771.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $333441.0 in Q4 2021 and bottomed at -$196281.0 in Q3 2023.
  • Average Interest Expenses over 5 years is $49085.3, with a median of $6856.0 recorded in 2024.
  • The sharpest move saw Interest Expenses skyrocketed 3149.88% in 2022, then crashed 1095.96% in 2024.
  • Year by year, Interest Expenses stood at $333441.0 in 2021, then crashed by 71.16% to $96175.0 in 2022, then crashed by 89.87% to $9745.0 in 2023, then plummeted by 1095.96% to -$97056.0 in 2024, then skyrocketed by 107.04% to $6835.0 in 2025.
  • Business Quant data shows Interest Expenses for CPHI at $6835.0 in Q3 2025, $6771.0 in Q2 2025, and $6787.0 in Q1 2025.